By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



3, avenue des Tropiques
B.P. 305 - Les Ulis
Courtaboeuf   Cedex  91958  France
Phone: 33-0-1-69-827010 Fax: 33-0-1-69-071903


Company News
LFB S.A. Announced Today The Acceptance By U.S. FDA Of The Filed Biologic License Application For Coagulation Factor VIIa Recombinant, (Eptacog Beta Activated) 1/6/2017 11:01:13 AM
FibCLOT, Human Fibrinogen From LFB S.A., Obtains First Marketing Authorizations In Europe 2/22/2016 2:32:24 PM
LFB S.A. Increases Its Capital By 230 Million Euros 10/12/2015 10:53:44 AM
First Marketing Authorizations In Europe For IQYMUNE, LFB S.A.’s 10% Liquid Intravenous Immunoglobulin 9/21/2015 10:51:06 AM
LFB S.A. Receives Go Ahead From Data Monitoring Committee To Expand The Global PERSEPT Phase 3 Program Of LR769 In Hemophilia A Or B Patients With Inhibitors 3/24/2015 11:08:44 AM
LFB S.A. Announces That First Patient Has Begun Treatment With New Coagulation Factor VIIa (Recombinant) In Global Phase 3 Clinical Trial In Hemophilia A And B With Inhibitors 5/14/2014 10:16:04 AM
LFB S.A. Initiates Global Phase 3 Clinical Trial Of New Coagulation Factor Viia (Recombinant) In Patients With Hemophilia A And B 3/3/2014 9:17:36 AM
LFB S.A.'s Recombinant Anti-CD20 Monoclonal Antibody is Granted Orphan Drug Status in the USA for Chronic Lymphocytic Leukemia 8/26/2010 8:14:08 AM
GTC Biotherapeutics (GTCB) Announces Conversion of LFB S.A.'s Preferred Stock into Common Shares and Provides a Portfolio Update 1/8/2010 10:20:41 AM
The French Biopharmaceutical Group LFB S.A. Has Announced the First-in-Man Injections of Its First Two Therapeutic Monoclonal Antibodies and the Filing of BLAs for a New-Generation Immunoglobulin and a Fibrinogen 2/10/2009 10:04:33 AM